Screening Assessment of Talc by Health Canada
In Canada, Talc was identified as a priority substance for assessment, so the Minister of the Environment and the Minister of Health performed a screening assessment of this compound. Regarding inhalation and perineal exposure, Talc may constitute a potential danger to human life or health.

TALC

Talc (CAS number: 14807-96-6) is a naturally occurring mineral, consisting of hydrous magnesium silicate and it can contain sometimes small quantities of aluminium silicate. It used in cosmetics and personal care products as an abrasive, absorbent, anticaking, bulking, opacifying and skin protecting agent. According to the European Cosmetics Regulation (EC) No 1223/2009, Talc is included in the list of substances which cosmetic products must not contain except subject to the restrictions laid down (Annex III, entry 59). In the European Union (EU), products containing Talc must have a caution statement to ensure safe use for children under 3 years of age, addressing the potential over-inhalation. The U.S. Food and Drug Administration (FDA) includes Talc (magnesium silicate) on its list of substances Generally Recognized As Safe (GRAS) for use in food as an anticaking agent and it also allows the use of talc as an indirect food additive (colourant in polymers) and as colourant in drugs.

TALC’S SCREENING ASSESSMENT

In Canada, Talc is used in a similar way to the rest of the world, as a food additive, in cosmetic products and in a wide range of other products (e.g. textiles, adhesives and sealants, toys, plastic and rubber materials, etc.). Canada’s Minister of the Environment and Minister of Health have performed a screening assessment of Talc (pursuant to section 74 of the Canadian Environmental Protection Act, 1999 – CEPA).

There were no critical health effects identified via the oral (food intake) or dermal (self-care products) routes of exposure. So, the focus of the screening assessment performed by Health Canada was the perineal and inhalation exposure to certain self-care products containing cosmetic- or pharmaceutical-grade Talc.

Based on studies conducted in rats and mice by the U.S National Toxicology Program (NTP), Talc may induce non-cancer lung effects, such as inflammation, impaired lung function and fibrosis. There is a potential for inhalation exposure to talc powder during the use of some self-care products (cosmetics, natural health products, non-prescription drugs formulated as loose powders, and not as pressed powders).

The experts also considered that, according to available human studies (peer-reviewed literature), there is a “consistent and statistically significant positive association between perineal exposure to talc and ovarian cancer”. The available data are indicative of a casual effect and, since there is a potential for perineal exposure to talc form the use of certain personal care products (such as body or baby powder, diaper and rash creams, genital antiperspirants and deodorants, body wipes, bath bombs, bubble bath), consequently it was concluded that there is a potential human health concern.

Talc is determined to be persistent but it didn’t meet the bioaccumulation criteria (set out in the Persistence and Bioaccumulation Regulations of CEPA) and was considered to be of low risk to harm the environment.

In sum, most of consumer products containing Talc are not of concern to human life or health. But when talking about certain products and its inhalation and perineal exposure, the conclusion obtained by Health Canada in its screening assessment was that Talc “is entering or may enter the environment in a quantity or concentration or under conditions that constitute or may constitute a danger in Canada to human life or health”. Consumers should avoid cosmetic products containing talc in the form of loose powders or which are intended for the genital area.

If you wish to get more information regarding this or other subjects, feel free to contact us at info@criticalcatalyst.com.

References:

  1. Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products – https://ec.europa.eu/health/sites/health/files/endocrine_disruptors/docs/cosmetic_1223_2009_regulation_en.pdf
  2. Screening Assessment Talc (Mg3H2(SiO3)4). Government of Canada – https://www.canada.ca/en/environment-climate-change/services/evaluating-existing-substances/screening-assessment-talc.html#toc0

further
reading

medical devices

Safety Reporting in Clinical Investigations: a Gap Analysis of Guidance Documents 

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Read More »
medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Read More »
medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Read More »
medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »
parfum_fragrance_allergen_1
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »